Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with...
Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, today announced it has completed a $39.6 million Series A...
View ArticleJANUMET results in greater blood sugar reductions in patients with type 2...
New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in...
View ArticleAmerican Regent initiates voluntary recall of Sodium Bicarbonate Injection,...
American Regent is conducting a nationwide voluntary recall to the consumer and user level of ALL unexpired lots of the following products:Sodium Bicarbonate Injection, USP, 7.5%, 44.6 mEq/50 mL,...
View ArticleFDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes
Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S....
View ArticleConference reviews recent evidence that links aspirin use with reduced risk...
Recent evidence linking aspirin use with a reduced risk of several cancers could change the risk benefits analysis in favour of wider use of aspirin, concluded a meeting organized by the Aspirin...
View ArticleFDA approves Shire's Lialda for maintenance of remission of ulcerative colitis
Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of...
View ArticleADHD diet: Review of studies
A new review finds that some foods may not be good for children with attention deficit-hyperactivity disorder (ADHD). Fast foods, red meat, processed foods, soft drinks, high fat dairy foods and potato...
View ArticleTop-line results from Shire's SPD476 phase 3 trial on diverticulitis
Shire plc, the global specialty biopharmaceutical company, today announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with...
View ArticleNew evidence helps explain additional health benefits of aspirin
New evidence is helping explain additional health benefits of aspirin. Researchers in Canada, Scotland and Australia have discovered that salicylate, the active ingredient in aspirin, directly...
View ArticleSimple urine test picks up mesalamine non-adherence
A readily available urine test could identify ulcerative colitis patients who are non-adherent to their mesalamine therapy, research shows.
View ArticleGout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES
Gout is the most common form of inflammatory arthritis that affects adults. It's a disease caused by the presence of uric acid crystals in and around the joints. It's a disease that's becoming more and...
View ArticleUlcerative colitis control: an interview with Dr Paul Robinson, Medical...
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which means there is chronic inflammation and ulceration in the lining of the digestive tract, usually in the large intestine.
View ArticleSalicylates drugs reduce proliferation, viability of cultured vestibular...
Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology's Program in Speech and Hearing Bioscience and Technology have demonstrated that...
View ArticleIroko announces availability of VIVLODEX capsules in U.S. pharmacies for...
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that VIVLODEX (meloxicam) capsules, a nonsteroidal...
View ArticleConference reviews recent evidence that links aspirin use with reduced risk...
Recent evidence linking aspirin use with a reduced risk of several cancers could change the risk benefits analysis in favour of wider use of aspirin, concluded a meeting organized by the Aspirin...
View ArticleFDA approves Shire's Lialda for maintenance of remission of ulcerative colitis
Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of...
View ArticleADHD diet: Review of studies
A new review finds that some foods may not be good for children with attention deficit-hyperactivity disorder (ADHD). Fast foods, red meat, processed foods, soft drinks, high fat dairy foods and potato...
View ArticleTop-line results from Shire's SPD476 phase 3 trial on diverticulitis
Shire plc, the global specialty biopharmaceutical company, today announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with...
View ArticleNew evidence helps explain additional health benefits of aspirin
New evidence is helping explain additional health benefits of aspirin. Researchers in Canada, Scotland and Australia have discovered that salicylate, the active ingredient in aspirin, directly...
View ArticleSimple urine test picks up mesalamine non-adherence
A readily available urine test could identify ulcerative colitis patients who are non-adherent to their mesalamine therapy, research shows.
View Article